Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Y Shi, L Zhang, X Liu, C Zhou, S Zhang, D Wang… - The lancet …, 2013 - thelancet.com
Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity
and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib …
被引用次数：531 相关文章

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Y Shi, L Zhang, X Liu, C Zhou, S Zhang, D Wang… - The Lancet …, 2013 - Elsevier
Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity
and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib …

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.

Y Shi, L Zhang, X Liu, C Zhou, S Zhang… - The Lancet …, 2013 - europepmc.org
Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity
and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib …

[引用][C] Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Y Shi, L Zhang, X Liu, C Zhou, S Zhang, D Wang… - The Lancet …, 2013 - cir.nii.ac.jp
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN):
a randomised, double-blind phase 3 non-inferiority trial | CiNii Research CiNii 国立情報学 …

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Y Shi, L Zhang, X Liu, C Zhou, S Zhang, D Wang, Q Li… - Lancet Oncol, 2013 - thelancet.com
Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity
and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib …

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Y Shi, L Zhang, X Liu, C Zhou, S Zhang… - The Lancet …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity
and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib …

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Y Shi, L Zhang, X Liu, C Zhou, S Zhang, D Wang… - The Lancet …, 2013 - infona.pl
Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity and
favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib is …

[引用][C] Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Y Shi, L Zhang, X Liu, C Zhou, S Zhang, D Wang… - Lancet …, 2013 - Elsevier Limited